Unlocking the potential of epigenetic therapeutics to revolutionize medicine

DURECT harnesses epigenetic regulation to treat acute and chronic organ injury. Our unique approach has the potential to change the course of disease and improve patients’ lives.

Epigenetic Regulation

Many types of organ injuries and chronic diseases are associated with dysregulation of the epigenome. There is vast potential for epigenetic therapies to address the underlying pathology of disease by mitigating epigenomic dysregulation and helping to improve cellular function.^1-3

Alcohol-Associated Hepatitis (AH)

Our first epigenetic therapy, larsucosterol (DUR-928), may have the potential to become a new standard of care for patients with AH based on outcomes from clinical trials to date.⁴

Clinical Trials

We are currently conducting a Phase 2b study (AHFIRM) in subjects with Alcohol-Associated Hepatitis (AH) in more than 60 clinical trial sites across the US, EU, UK, and Australia.

Partner with us

We welcome strategic partnerships to advance our collective goal to meaningfully impact patients’ lives and offer better therapeutic options.

Careers

Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies.

Press Releases

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

September 7, 2023

07 Sep, 2023, 07:00 ET Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif., Sept. 7, 2023 /PRNewswire/ — DURECT Corporation

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

August 31, 2023

31 Aug, 2023, 16:30 ET CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of

References

Argemi J, Latasa MU, Atkinson SR, et al. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun. 2019;10(1):3126. doi:10.1038/s41467-019-11004-3
Mazzone R, Zwergel C, Artico M, et al. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenetics. 2019;11(1):34. doi:10.1186/s13148-019-0632-2
Herman A, Occean JR, Sen P. Epigenetic dysregulation in cardiovascular aging and disease. J Cardiovasc Aging. 2021;1:10. doi:10.20517/jca.2021.16
Hassanein T, Stein L, Flamm S, et al. Safety and efficacy of DUR-928: A potential new therapy for acute alcoholic hepatitis. Late-breaking oral presentation at AASLD The Liver Meeting®; 2019 November 12.

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_4G64V72Q46	2 years	This cookie is installed by Google Analytics.
_pk_id.120285.a7d5	1 year 27 days	Used by Motomo Analytics to store a few details about the user such as the unique visitor ID.
_pk_ses.120285.a7d5	30 minutes	Short lived cookies used by Motomo Analytics to temporarily store data for the visit.

Cookie	Duration	Description
c	6 months 2 days	This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services.
uuid	1 year 27 days	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.